id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-332087-xwturwju	McGlynn, Fergal	Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection	2020-08-24		.txt	text/plain	1448	101	54	They describe their experience with Covid-19 patients in the intensive care unit anti-coagulated with low molecular weight heparin (LMWH) and unfractionated heparin (UFH), presenting evidence of apparent heparin resistance (HR) resulting from increased levels of factor VIII and fibrinogen with decreased antithrombin levels. [4] recently reported outcomes for 42 patients in (non-Covid-19) critical care settings with HR who were anti-coagulated with argatroban compared to those treated with increased doses of UFH. They reported greater efficacy in achieving adequate anti-coagulation (as measured by the aPTT) at 24 h with argatroban than with increased doses of heparin. We report 2 cases of apparent HR in critically ill Covid-19 patients with thrombotic complications who were successfully and safely treated with argatroban. Argatroban may be considered as an alternative anti-coagulant, easily monitored using the aPTT in critically ill patients with Covid-19-associated thrombosis and HR.	./cache/cord-332087-xwturwju.txt	./txt/cord-332087-xwturwju.txt